Genmab AS (GMAB : NASDAQ)
Common Stock
$38.48
USD
+3.73 (10.73%)
Last updated: 2026-10-05
Follow GMAB
GMAB
Genmab AS
WealthAwesomePerformance
1 Day
+10.73%
1 Week
+8.82%
1 Month
+14.52%
YTD
+20.93%
Key Statistics
Market Cap
$24.01B
52W High
$40.17
52W Low
$23.62
P/E Ratio
27.49
50 Day MA
$32.67
200 Day MA
$29.63
Beta
0.65
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/5/2026 | $35.09 | $40.17 | $35.02 | $38.48 | $38.48 | 12,403,391 |
| 10/2/2026 | $34.39 | $35.02 | $33.73 | $34.75 | $34.75 | 5,436,400 |
| 10/1/2026 | $35.25 | $35.80 | $34.52 | $34.55 | $34.55 | 6,377,000 |
| 9/30/2026 | $35.72 | $35.91 | $35.37 | $35.67 | $35.67 | 5,154,400 |
| 9/29/2026 | $34.94 | $35.64 | $34.89 | $35.57 | $35.57 | 3,827,500 |
| 9/28/2026 | $34.76 | $35.70 | $34.63 | $35.36 | $35.36 | 2,794,600 |
| 9/25/2026 | $34.95 | $35.47 | $34.70 | $35.32 | $35.32 | 3,583,100 |
| 9/24/2026 | $34.69 | $35.03 | $34.36 | $34.83 | $34.83 | 2,514,900 |
| 9/23/2026 | $35.39 | $35.66 | $34.60 | $34.75 | $34.75 | 2,509,700 |
| 9/22/2026 | $34.46 | $35.30 | $34.37 | $35.22 | $35.22 | 2,297,600 |
Analyst Price Targets
Based on 11 analysts covering GMAB · as of Oct 6, 2026
Wall Street analysts forecast GMAB stock price to rise 6.3% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
US$40.92
+6.3% Upside
Previously US$39.05 on Oct 5, 2026
Current Price
US$38.48
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
40.3%
Annualized
90-Day Vol
35.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$46.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$40.84 | US$35.53 – US$46.94 |
| 60 trading days | US$43.34 | US$35.60 – US$52.77 |
| 90 trading days | US$46.00 | US$36.15 – US$58.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Financials
- Revenue (TTM)
- $4.13B
- EBITDA
- $1.38B
- Profit Margin
- 19.08%
- ROE (TTM)
- 14.00%
- EPS (Diluted)
- 1.40
- Book Value
- 9.98
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GMAB.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GUTS | Fractyl Health, Inc. Common Stock | $4.56 | +1020.39% |
| CMND | Clearmind Medicine Inc. Common Shares | $6.00 | +739.16% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.24 | +74.48% |
| VEEA | Veea Inc. | $5.72 | +71.77% |
| PDSB | PDS Biotechnology Corp | $1.20 | +60.21% |
| BEAT | Heartbeam Inc | $0.65 | +50.39% |
| RITRF | Reitar Logtech Holdings Limited | $0.01 | +42.86% |
| QTEX | QTREX Quantum Ltd. | $1.54 | +40.00% |
GMAB.US news timeline
1 article covering GMAB.US, most recent first
Latest